Top Things to Know: 2023 Guideline for the Management of Patients With Chronic Coronary Disease

Published: July 20, 2023

  1. Emphasis is on team-based, patient-centered care that considers social determinants of health (SDOH) along with associated costs while incorporating shared decision-making in risk assessment, testing, and treatment.
  2. Chronic coronary disease (CCD) is heterogeneous group of conditions that includes obstructive and nonobstructive CAD with or without previous myocardial infarction (MI) or revascularization, ischemic heart disease diagnosed only by noninvasive testing, and chronic angina syndromes with varying underlying causes.
  3. Nonpharmacologic therapies, including healthy dietary habits and exercise, are recommended for all patients with CCD.
  4. Patients with CCD who are free from contraindications are encouraged to participate in habitual physical activity, including activities to reduce sitting time and to increase aerobic and resistance exercise. Cardiac rehabilitation for eligible patients provides significant cardiovascular benefits, including decreased morbidity and mortality outcomes.
  5. Use of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists are recommended for select groups of patients with CCD, including groups without diabetes.
  6. New recommendations for beta-blocker use in patients with CCD: (a) Long-term beta-blocker therapy is not recommended to improve outcomes in patients with CCD in the absence of myocardial infarction in the past year, left ventricular ejection fraction ≤50%, or another primary indication for beta-blocker therapy; and (b) Either a calcium channel blocker or beta blocker is recommended as first-line antianginal therapy.
  7. Statins remain first line for lipid lowering in patients with CCD. Several adjunctive therapies (eg, ezetimibe, proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors, inclisiran, bempedoic acid) may be used in select populations, although clinical outcomes data are not yet available for novel agents such as inclisiran and bempedoic acid.
  8. Shorter durations of dual antiplatelet therapy are safe and effective in many circumstances, particularly when the risk of bleeding is high and the ischemic risk is not high.
  9. The use of nonprescription or dietary supplements, including fish oil and omega-3 fatty acids or vitamins, is not recommended in patients with CCD given the lack of benefit in reducing cardiovascular events.
  10. Routine periodic anatomic or ischemic testing without a change in clinical or functional status is not recommended for risk stratification or to guide therapeutic decision-making in patients with CCD.
  11. Although they increase the likelihood of successful smoking cessation compared to nicotine replacement therapy, because of the lack of long-term safety data and risks of sustained use, e-cigarettes are not recommended as first-line therapy for smoking cessation.


Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a reportof the American Heart Association/American College of Cardiology Joint Committee on Clinical PracticeGuidelines [published online ahead of print July 20, 2023]. Circulation. doi: 10.1161/CIR.0000000000001168